Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease
Identifieur interne : 001C57 ( Main/Exploration ); précédent : 001C56; suivant : 001C58Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease
Auteurs : Cheryl Waters [États-Unis]Source :
- Journal of the American Geriatrics Society [ 0002-8614 ] ; 2000-06.
English descriptors
- KwdEn :
Abstract
Catechol‐O‐methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease. COMT inhibitors act by extending the duration of action of levodopa, thus improving the amount of time a patient can experience benefit from levodopa. COMT inhibitors are only used in conjunction with levodopa. They do have a propensity to augment dopaminergic effects, such that levodopa doses might need to be adjusted downward. Other side effects of COMT inhibitors include diarrhea and liver function abnormalities. Due to the latter, recent guidelines have been developed to monitor patients on tolcapone for this rare side effect, and these guidelines will be discussed. This article also provides representative case histories for the appropriate use of COMT inhibitors that illustrate how these drugs can be used to manage patients with a fluctuating response to levodopa. J Am Geriatr Soc 48:692–698, 2000.
Url:
DOI: 10.1111/j.1532-5415.2000.tb04732.x
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease</title><author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:20DD48E951688335F38C24FE188C626B31DE444A</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1111/j.1532-5415.2000.tb04732.x</idno><idno type="url">https://api.istex.fr/document/20DD48E951688335F38C24FE188C626B31DE444A/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001D38</idno><idno type="wicri:Area/Main/Curation">001A58</idno><idno type="wicri:Area/Main/Exploration">001C57</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease</title><author><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Columbia University, Department of Neurology, New York</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the American Geriatrics Society</title><idno type="ISSN">0002-8614</idno><idno type="eISSN">1532-5415</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2000-06">2000-06</date><biblScope unit="volume">48</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="692">692</biblScope><biblScope unit="page" to="698">698</biblScope></imprint><idno type="ISSN">0002-8614</idno></series><idno type="istex">20DD48E951688335F38C24FE188C626B31DE444A</idno><idno type="DOI">10.1111/j.1532-5415.2000.tb04732.x</idno><idno type="ArticleID">JGS4732</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0002-8614</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COMT inhibitors</term><term>Parkinson's disease</term><term>entacapone</term><term>levodopa</term><term>tolcapone</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Catechol‐O‐methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease. COMT inhibitors act by extending the duration of action of levodopa, thus improving the amount of time a patient can experience benefit from levodopa. COMT inhibitors are only used in conjunction with levodopa. They do have a propensity to augment dopaminergic effects, such that levodopa doses might need to be adjusted downward. Other side effects of COMT inhibitors include diarrhea and liver function abnormalities. Due to the latter, recent guidelines have been developed to monitor patients on tolcapone for this rare side effect, and these guidelines will be discussed. This article also provides representative case histories for the appropriate use of COMT inhibitors that illustrate how these drugs can be used to manage patients with a fluctuating response to levodopa. J Am Geriatr Soc 48:692–698, 2000.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Waters, Cheryl" sort="Waters, Cheryl" uniqKey="Waters C" first="Cheryl" last="Waters">Cheryl Waters</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C57 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001C57 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:20DD48E951688335F38C24FE188C626B31DE444A
|texte= Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |